The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million ...

Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply ...

While Isomorphic is an independent unit of Google parent Alphabet, Hassabis' dual roles reflect the intertwined relationship between the two parties. Isomorphic has never revealed how much Google ...

It will receive follow-on capital from existing backer Alphabet. The London-based company’s goal is an ambitious one – to “solve all disease,” according to the Isomorphic Labs site.